Protein S Heerlen mutation heterozygosity is associated with venous thrombosis risk

P. Suchon1,2, M. Germain1,4, A. Delluc5, D. Smadja6,7, X. Jouven8,9,10, B. Gyorgy3,4, N. Saut1, M. Ibrahim1,2, J. F. Deleuze11,12, M. C. Alessi1,2, P. E. Morange1,2,* & D. A. Trégouët3,4,*

Hereditary Protein S (PS) deficiency is a rare coagulation disorder associated with an increased risk of venous thrombosis (VT). The PS Heerlen (PSH) mutation is a rare S501P mutation that was initially considered to be a neutral polymorphism. However, it has been later shown that PSH has a reduced half-life in vivo which may explain the association of PSH heterozygosity with mildly reduced levels of plasma free PS (FPS). Whether the risk of VT is increased in PSH carriers remains unknown. We analyzed the association of PSH (rs121918472 A/G) with VT in 4,173 VT patients and 5,970 healthy individuals from four independent case-control studies. Quantitative determination of FPS levels was performed in a subsample of 1257 VT patients. In the investigated populations, the AG genotype was associated with an increased VT risk of 6.57 [4.06–10.64] (p = 1.73 × 10−3). In VT patients in whom PS deficiency was excluded, plasma FPS levels were significantly lower in individuals with PSH when compared to those without [72 ± 13 vs 91 ± 21 UI/dl; p = 1.86 × 10−5, mean + SD for PSH carriers (n = 21) or controls (n = 1236) respectively]. We provide strong evidence that the rare PSH variant is associated with VT in unselected individuals.

Protein S (PS) is a potent anticoagulant protein that down regulates thrombin formation via two mechanisms. It can stimulate the proteolytic inactivation of coagulation factors Va and VIIIa by activated protein C (APC), and can also enhance FXa inhibition by interacting with tissue factor pathway inhibitor (TFPI). Although free PS (FPS) is the most active PS form, recent reports indicate that the PS-C4BP complex also exhibits APC- and TFPI cofactor activities.

Hereditary PS deficiency is a rare coagulation disorder associated with an increased risk of venous thrombosis (VT). As for other deficiencies in natural anticoagulant inhibitors (antithrombin and protein C), PS deficiency is due to rare or private mutations within the PROS1 gene (database available online: http://www.hgmd.cf.ac.uk). Among these, the rs121918472 variation—referred to as the PS Heerlen mutation—is detected at a high frequency in the general population (0.5%). PS Heerlen is a S501P amino acid change polymorphism that causes a loss of N-linked glycosylation at position 4996, and was initially considered a neutral polymorphism. However, it was later shown that 1) PS Heerlen has a reduced half-life in vivo, 2) and that heterozygous and homozygous PS Heerlen genotypes were associated with mildly reduced or low levels of plasma FPS, respectively. Moreover, PS Heerlen was found to increase thrombin generation in the presence of APC compared to wild type PS. Thus whether VT risk is increased in PS Heerlen heterozygous subjects remains uncertain. Indeed, Bertina et al. found no differences in mutation prevalence in a panel of 96 uncharacterized normal individuals as compared to 1,182

1Laboratory of Haematology, La Timone Hospital, Marseille, France. 2Institut National pour la Santé et la Recherche Médicale (INSERM), Unité Mixte de Recherche en Santé (UMR_S) 1062, Nutrition Obesity and Risk of Thrombosis, Aix-Marseille University, Marseille, France. 3Sorbonne Universités, UPMC Univ. Paris 06, INSERM, UMR_S 1166, Team Genomics & Pathophysiology of Cardiovascular Diseases, Paris, France. 4ICAN Institute for Cardiometabolism and Nutrition, Paris, France. 5Université de Brest, EA3878 and CIC1412, 29238 Brest, France. 6Service d’hématologie biologique, AP-HP, Hôpital Européen Georges Pompidou, Paris, France. 7ICAN Institute for Cardiometabolism and Nutrition, Paris, France. 8Inserm UMR-S1140, Paris, France. 9Centre National de Génotypage, Institut de Génomique, CEA, 91057 Eyré, France. 10APHP, Georges Pompidou European Hospital, Department of Cardiology, Paris, France. 11ICAN Institute for Cardiometabolism and Nutrition, Paris, France. 12CEPH, Fondation Jean Dausset, Paris, France. *These authors contributed equally to this work. Correspondence and requests for materials should be addressed to P.E.M. (email: pierre.morange@ap-hm.fr)
Dutch patients with unexplained VT (0.52% vs 0.68% respectively)\(^9\). Apart from this study with poorly described patients, the impact of PS Heerlen on VT has only been studied in families either with PS deficiency or with other combined genetic or acquired risk factors. In these situations, PS Heerlen was thought to increase VT risk. In the INVENT GWAS projects by INVENT\(^11\) and 23 and Me consortia\(^12\). In the INVENT GWAS, the Heerlen mutation was not identified as a VT-associated polymorphism in the two most recent VT GWAS projects by INVENT\(^11\) and 23 and Me consortia\(^12\). In the INVENT GWAS, the Heerlen mutation imputation quality was extremely low, \(r^2 = 0.15^{11}\), which is far lower than the gold standard of \(r^2 > 0.8\) for imputation quality, and the increased risk associated with the imputed rs121918472-G allele was OR \(= 1.46\) [0.28–7.58], \(p = 0.655\). Because 865 MARTHA/EOVT participants examined in the current study also took part in the INVENT study, we were able to calculate the Spearman correlation between the true rs121918472 genotype as provided by Illumina Exome array results, and the imputed dose-derived from GWAS arrays. The resulting low correlation of \(\rho = 0.25\) illustrates how imputation techniques are not reliable for inferring rare variants such as rs121918472.

To provide additional evidence implicating rs121918472 in increased VT risk, we assessed its association with plasma FPS levels in the MARTHA study samples. Even if by design FPS deficiency was excluded in this study, plasma FPS levels were significantly lower in individuals with PS Heerlen (\(p = 1.86 \times 10^{-4}\)) compared to those without (mean ± standard deviation: 72 ± 13 vs 91 ± 21 UI/dL, respectively) (Fig. 1).

**Discussion**

In the present study we systematically analyzed four French case-control collections totalling 4,173 patients and 5,970 healthy individuals. In the investigated populations, the AG genotype was significantly more frequent in VT patients than in healthy controls, 2.2% vs 0.4%, respectively, and was also associated with an increased VT risk of 6.57. This association was significantly heterogeneous across studies (\(p < 0.001\)) due to strong associations in the EDITH cohort (2.4% vs 0%), the MARTHA12 cohort (2.5% vs 0.6%), the EOVT/MARTHA cohort (2.4% vs 0%) samples, but not in FARIVE study samples (1.1% vs 1.8%). Note that the observed AG genotype frequency was higher in FARIVE controls (2.7% vs 2.4%) than in those without (0.9%, n = 246) but in those without (0.9%, n = 343) in whom the frequency was similar to the other cohort controls. Excluding the FARIVE study from the combined analysis increased the significance of the association between rs121918472 and VT (OR = 14.58 [7.42–28.65], \(p = 7.66 \times 10^{-15}\)).

We also examined whether the rs121918472-G allele frequency varied in specific VT subgroups, such as in patients with provoked or unprovoked VT, patients with deep vein thrombosis or pulmonary embolism, and patients with F5 or F2 G20210A mutations. We did not observe preferential associations in any specific strata.

Interestingly, the rs121918472 variant was not identified as a VT-associated polymorphism in the two most recent VT GWAS projects by INVENT\(^11\) and 23 and Me consortia\(^12\). In the INVENT GWAS, the Heerlen mutation imputation quality was extremely low, \(r^2 = 0.15^{11}\), which is far lower than the gold standard of \(r^2 > 0.8\) for imputation quality, and the increased risk associated with the imputed rs121918472-G allele was \(OR = 1.46\) [0.28–7.58], \(p = 0.655\). Because 865 MARTHA/EOVT participants examined in the current study also took part in the INVENT study, we were able to calculate the Spearman correlation between the true rs121918472 genotype as provided by Illumina Exome array results, and the imputed dose-derived from GWAS arrays. The resulting low correlation of \(\rho = 0.25\) illustrated how imputation techniques are not reliable for inferring rare variants such as rs121918472.

**Results**

Genotype distributions of the rs121918472 variant within the four case-control collections are shown in Table 1. No homozygous carrier of the rare rs121918472-G allele was observed. When samples were combined, the AG genotype was more frequent in VT patients than in healthy controls, 2.2% vs 0.4%, respectively, and was associated with an increased VT risk (Odds Ratio OR) of 6.57 [4.06–10.64] (\(p = 1.73 \times 10^{-14}\)). The association was significantly heterogeneous across studies (\(p < 0.001\)) due to strong associations in the EDITH cohort (2.4% vs 0%), the MARTHA12 cohort (2.5% vs 0.6%), the EOVT/MARTHA cohort (2.4% vs 0%) samples, but not in FARIVE study samples (1.1% vs 1.8%). Note that the observed AG genotype frequency was higher in FARIVE controls (2.7% vs 2.4%) than in those without (0.9%, n = 246) but in those without (0.9%, n = 343) in whom the frequency was similar to the other cohort controls. Excluding the FARIVE study from the combined analysis increased the significance of the association between rs121918472 and VT (OR = 14.58 [7.42–28.65], \(p = 7.66 \times 10^{-15}\)).

We also examined whether the rs121918472-G allele frequency varied in specific VT subgroups, such as in patients with provoked or unprovoked VT, patients with deep vein thrombosis or pulmonary embolism, and patients with F5 or F2 G20210A mutations. We did not observe preferential associations in any specific strata.

Interestingly, the rs121918472 variant was not identified as a VT-associated polymorphism in the two most recent VT GWAS projects by INVENT\(^11\) and 23 and Me consortia\(^12\). In the INVENT GWAS, the Heerlen mutation imputation quality was extremely low, \(r^2 = 0.15^{11}\), which is far lower than the gold standard of \(r^2 > 0.8\) for imputation quality, and the increased risk associated with the imputed rs121918472-G allele was \(OR = 1.46\) [0.28–7.58], \(p = 0.655\). Because 865 MARTHA/EOVT participants examined in the current study also took part in the INVENT study, we were able to calculate the Spearman correlation between the true rs121918472 genotype as provided by Illumina Exome array results, and the imputed dose-derived from GWAS arrays. The resulting low correlation of \(\rho = 0.25\) illustrated how imputation techniques are not reliable for inferring rare variants such as rs121918472.

| Genotype | Controls | Cases |
|----------|----------|-------|
| AA       | 5970 (99.6%) | 4173 (97.8%) |
| AG       | 22 (0.4%) | 94 (2.2%) |
| GG       | 0 | 0 |

**Table 1. Association of the PROS1 rs121918472 (PS Heerlen mutation) with VT in four French case-control sample studies.** The frequency of AG genotype was 2.7% and 2.4% in EOVT and MARTHA VT patients, respectively.

---

### Controls

| Study | Cases | Controls |
|-------|-------|----------|
| EDITH | 156 (99.6%) | 1117 (97.6%) |
| FARIVE | 657 (98.2%) | 3379 (100%) |
| MARTHA | 768 (99.4%) | 1603 (97.6%) |
| EOVT/MARTHA | 734 (97.5%) | 1117 (97.6%) |

**Table 1. Association of the PROS1 rs121918472 (PS Heerlen mutation) with VT in four French case-control sample studies.** The frequency of AG genotype was 2.7% and 2.4% in EOVT and MARTHA VT patients, respectively.
association pattern was evident in EDITH, MARTHA, and EOVT/MARTHA samples, but not in FARIVE study samples. There is no apparent explanation for the surprisingly high PS Heerlen mutation prevalence in apparently healthy individuals from the FARIVE study (1.8%). This observation could be due to the study design, as controls were actually matched cardiology patients without VT, and not healthy individuals from the general population. The significantly increased thrombosis risk associated with this mutation supports the concept that PS Heerlen has deleterious effects on the disease. However, PS Heerlen is usually classified as a neutral polymorphism, both via bioinformatics prediction tools or by functional studies where it only slightly affects FSP levels in plasma. Of note, no homozygous carrier was identified in any of the four case-control studies. This observation was entirely compatible with data from the ExAC (Exome Aggregation Consortium) database, in which only one individual was homozygous for PS Heerlen among the ~33,000 studied subjects of European origin. This low frequency is likely due to the fact that homozygous carriers are considered to be protein S deficient, a condition with high morbidity. There is one PS Heerlen homozygous patient documented in the literature, with very low levels of free protein S (34%)\textsuperscript{13}. In the MARTHA study, even if FSP deficiency was excluded by design, plasma FSP levels were significantly lower in individuals with PS Heerlen compared to those without. Assessing whether the disease effect is completely mediated through a direct effect on decreased FSP levels would require further investigations, including epidemiological studies where both the PSH mutation and FSP levels are measured in case-control samples. However, due to the extremely low frequency of the PSH variation in well matched control population, it will be nearly impossible to conduct mediation analysis to properly assess whether the effect of the mutation on disease risk is completely due to its effect on lowering FSP levels. However, in an additional population based study, only very low levels of FPS (<1/10\textsuperscript{th} percentile or <33 UI/dl) were associated with increased VT risk\textsuperscript{1,14}, suggesting that the effect of PS Heerlen on VT risk might thus be related to mechanisms other than solely half-life reduction. However, recombinant PS Heerlen does not differ in either binding to, or dissociation to or from, immobilized C4BP \textit{in vitro}, nor does it show any differences in the inactivation of FVa or FVIII\textsuperscript{15}. PS is also a cofactor for TFPI, and accelerates the inhibition of activated factor X (FXa). The PS Heerlen mutation is located within the SHBG-like domain (Val243-Ser635) critical for TFPI binding and enhancement\textsuperscript{16}. Thus, one might hypothesize that PS Heerlen could affect thrombosis risk by impairing TFPI function.

The recent GWAS on VT has enabled the identification of several new VT susceptibility variants. Very recently, the INVENT consortium gathered 7,507 VT subjects and 52,632 controls and identified two new loci (SLC44A2 and TSPAN15) and robustly replicated six previously identified loci\textsuperscript{11}. PS Heerlen was not among the identified disease polymorphisms, likely because this GWAS relied on imputation techniques that were not optimal for inferring rare variants\textsuperscript{17}. The exome chip used in the present study was enriched by rare coding variants predicted to be causal. The results presented herein as well as those from the recently published paper on key hemostatic traits\textsuperscript{18} emphasize the promise of this new chip in identifying low-frequency variants associated with VT.

In conclusion, we provide evidence that PS Heerlen is associated with increased VT risk in individuals of the general population. Further investigations are required to better understand the surprisingly high prevalence of PS Heerlen mutation in apparently healthy individuals from the FARIVE study. Functional studies investigating the potential influence of PS Heerlen on VT risk would also be of benefit. These results also raise the question of whether PS Heerlen should always be genotyped irrespective of plasma PS levels in thrombophilia screening.

Methods

The present work utilized four case-control sample cohorts (EDITH, FARIVE, EOVT/MARTHA)\textsuperscript{11} where VT events (pulmonary embolism or deep vein thrombosis) were objectively diagnosed\textsuperscript{11}. Detailed descriptions of the four case-control sample groups are included in the supplementary text.

In the FARIVE and EDITH studies, the PS Heerlen variation was genotyped by High Resolution Melting (HRM). All EOVT and MARTHA patients were typed using the Illumina Human Exome Beadchip 12v1-2-A
array and compared to control participants from the Paris Prospective Study typed with the Human Exome Beadchip 12v1-A chip (Illumina, Inc., San Diego, CA). Both of these genotyping arrays were designed to assess coding variants across the whole genome. Data analysis revealed 239,569 single nucleotide polymorphisms common to both, including PS Heerlen rs121918472. Individuals with less than 98% genotyping success or high heterozygosity were excluded from the analyses, as were individuals demonstrating previously unknown close relatedness. The latter were separately assessed via pairwise clustering of identity by state distance (IBS) and multi-dimensional scaling (MDS) using PLINK software. Genetic outlier analysis was performed using IBS statistics and principal component analysis to detect individuals of non-European origin, who were then removed from the analysis. This led to a selected cohort of 2,630 VT patients and 3,414 controls typed with Illumina exome chips for final association analysis.

The overall rs121918472 genotype call rate was 0.98, with 0.97 in the FARIVE and EDITH studies typed with HRM, and 0.99 in individuals typed with the Illumina Human Exome chips.

In MARTHA, fasting blood was drawn for FPS measurement. Quantitative FPS determination was performed by enzyme-linked immunosorbent assay (ELISA) using the Asserachrom FPS assay (Diagnostica Stago). PS deficiency was defined as FPS plasma antigen levels <55 IU/dL using the specific ELISA assay. FPS data were available in 1,257 MARTHA individuals.

Genotype distribution of the rs121918472 was tested for deviation from Hardy-Weinberg (HW) equilibrium via the HW exact test. Association of rs121918472 with VT was analyzed via the Cochran-Armitage trend test and by logistic regression analysis adjusting for age and sex. Association of rs121918472 with FPS was assessed using linear regression analysis. Analyses were first performed separately in each study, and were then performed on all samples combined and further adjusted for the study group.

Informed consent was obtained from all participants and the study met all institutional ethics requirements. The procedures employed were reviewed and approved by the Assistance Publique des Hopitaux de Marseille institutional review committee.

References
1. Castoldi, E. &Hackeng, T. M. Regulation of coagulation by protein S. Curr Opin Hemat 15, 529–36 (2008).
2. Maurissen, L. F., Thomassen, M. C., Nicolae, G. A., Dahlbäck, B., Tans, G., Rosing, J. & Hackeng, T. M. Re-evaluation of the role of the protein S-C4b binding protein complex in activated protein C-catalyzed factor Va-inactivation. Blood 111, 3034–41 (2008).
3. Dahlbäck, B. C4b-binding protein: a forgotten factor in thrombosis and hemostasis. Semin Thromb Hemost. 37, 355–61 (2011).
4. Hackeng, T. M., Seré, K. M., Tans, G. &Rosing, J. Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor. Proc Natl Acad Sci USA 103, 3106–11 (2006).
5. Schwarz, H. P., Fischer, M., Hopmeier, P., Batard, M. A. &Griffin, J. H. Plasma protein S deficiency in familial thrombotic disease. Blood 64, 1297–300 (1984).
6. Bertina, R. M. et al. Heerlen polymorphism of protein S, an immunologic polymorphism due to dimorphism of residue 460. Blood 76, 538–48 (1990).
7. Denis, C. V., Roberts, S. J., Hackeng, T. M. & Lenting, P. J. In vivo clearance of human protein S in a mouse model: influence of C4b-binding protein and the Heerlen polymorphism. Arterioscler, ThrombVasc Biol. 25, 2209–15 (2005).
8. Duchemin, J. et al. The Ser 460 to Pro substitution of the protein S alpha (PROS1) gene is a frequent mutation associated with free protein S (type Ia) deficiency. Blood 86, 3436–43 (1995).
9. Alenc-Gelas, M., Canonico, M., Morange, P. E. & Emmerich, J. Geht Genetic Thrombophilia Group. Protein S inherited qualitative deficiency: novel mutations and phenotypic influence. J Thromb Haemost. 8, 2718–26 (2010).
10. Giri, T. K., Yamazaki, T., Sala, N., Dahlbäck, B. & de Frutos, P. G. Deficient APC-cofactor activity of protein S Heerlen in degradation of factor Va Leiden: a possible mechanism of synergism between thrombophilic risk factors. Blood 96, 523–31 (2000).
11. Germain, M. et al. Meta-analysis of 65,734 individuals identifies TSPAN15 and SLC44A2 as two susceptibility loci for venous thromboembolism. Am J Hum Genet 95, 532–42 (2015).
12. Hind, D. A. et al. Genome-wide association analysis of self-reported events in 6135 individuals and 252 827 controls identifies 8 loci associated with thrombosis. Hum Mol Genet 25, 1867–74 (2016).
13. Wypasek, E., Potaczek, D. P., Alenc-Gelas, M. & Undas, A. Heerlen polymorphism associated with type III protein S deficiency and factor V Leiden mutation in a Polish patient with deep vein thrombosis. Blood Coagul Fibrinolysis 25, 84–5 (2014).
14. Pinto, M. C. et al. Protein S levels and the risk of venous thrombosis: results from the MEGA case-control study. Blood 122, 3210–9 (2013).
15. Koenen, R. R., Gomes, L., Tans, G., Rosing, J. &Hackeng, T. M. The Ser460Pro mutation in recombinant protein S Heerlen does not affect its APC-cofactor and APC-independent anticoagulant activities. Thromb Haemost. 91, 1105–14 (2004).
16. Reglińska-Matveyev, N. et al. TFPI cofactor function of protein S: essential role of the protein S SHBG-like domain. Blood 123, 3979–87 (2014).
17. Manolio, T. A. Finding the missing heritability of complex diseases. Nature 461, 747–53 (2009).
18. Huffman, J. E. et al. Rare and low-frequency variants and their association with plasma levels of fibrinogen, FVII, FVIII, and vWF. Blood 126, 19–29 (2015).
19. Proust, C. et al. Contribution of Rare and Common Genetic Variants to Plasma Lipid Levels and Carotid Stiffness and Geometry: A Substudy of the Paris Prospective Study 3. Circ Cardiovasc Genet. 8, 628–36 (2015).
20. Purcell, S. et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 81, 559–75 (2007).

Acknowledgements
We are grateful to Rachel Peat for editing and grammatical corrections. This research was partially supported by the GENMED Laboratory of Excellence on Medical Genomics (ANR-10-LABX-0013), the French Clinical Research Infrastructure Network on Venous Thrombo-Embolism (F-CRIN INNOVTE) and the ICAN Institute for Cardiometabolism and Nutrition (ANR-10-IAHU-05), three research programs managed by the National Research Agency (ANR) as part of the French Investment for the Future initiative.
Author Contributions
P.S., M.G. and B.G. were in charge of statistical data analysis. N.S. and M.I. were in charge of the genotyping work. A.D., D.S., X.J., J.E.D., M.C.A., P.E.M. and D.A.T. designed the participating studies and the overall project. P.S. drafted the manuscript that was further revised by A.D., D.S., X.J., P.E.M. and D.A.T.

Additional Information
Supplementary information accompanies this paper at http://www.nature.com/srep

Competing Interests: The authors declare no competing financial interests.

How to cite this article: Suchon, P. et al. Protein S Heerlen mutation heterozygosity is associated with venous thrombosis risk. Sci. Rep. 7, 45507; doi: 10.1038/srep45507 (2017).

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

© The Author(s) 2017